OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Crafton on Considerations for Secondary Cytoreduction in Ovarian Cancer

February 19th 2020

Sarah Crafton, MD, discusses the personalized choice of undergoing secondary cytoreduction for patients with ovarian cancer.

Dr. Pasquini on Tisagenlecleucel in Real-World and Clinical Trial Settings in ALL and DLBCL

February 19th 2020

Marcelo Pasquini, MD, discusses the similarities between real-world experience with tisagenlecleucel and in the ELIANA and JULIET trials.

Dr. Fowler on Patient Eligibility for Cytoreductive Surgery in Ovarian Cancer

February 19th 2020

Jeffrey M. Fowler, MD, discusses patient eligibility for cytoreductive surgery in newly diagnosed ovarian cancer.

Dr. Freedland on a Real-World Analysis of Enzalutamide in mCRPC

February 19th 2020

Stephen J. Freedland, MD, discusses a real-world analysis of enzalutamide in metastatic castration-resistant prostate cancer.

Dr. Bakouny on the Role of Cytoreductive Nephrectomy in mRCC

February 19th 2020

Ziad Bakouny, MD, MSc, discusses the role of cytoreductive nephrectomy in metastatic renal cell carcinoma.

The Potential Utility of CLR 131 in Multiple Myeloma

February 19th 2020

Jarrod Longcor, MS, MBA, discusses the potential utility of the small-molecule radiotherapeutic phospholipid-drug conjugate CLR 131 in patients with multiple myeloma.

Dr. Cercek on the Impact of Tumor Sidedness on Frontline Treatment in mCRC

February 19th 2020

Andrea Cercek, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the impact of tumor sidedness on frontline treatment decisions in metastatic colorectal cancer (mCRC).

Dr. Weber on Emerging Immunotherapy Combinations in Melanoma

February 19th 2020

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the melanoma program, Laura and Isaac Perlmutter Professor of Oncology, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses emerging immunotherapy combinations in melanoma.

Dr. Wenham on Neoadjuvant Chemotherapy Versus Primary Debulking Surgery in Ovarian Cancer

February 19th 2020

Robert M. Wenham, MD, gynecologic oncologist and chair of the Department of Gynecologic Oncology at Moffitt Cancer Center, sheds light on the debate between neoadjuvant chemotherapy and primary debulking surgery in patients with newly diagnosed, advanced ovarian cancer.

Dr. Ilson on Investigative TKI Combinations in Gastric Cancer

February 18th 2020

David H. Ilson, MD, PhD, discusses TKI combinations under investigation in gastric cancer.

Dr. Vaishampayan on Systemic Therapy Followed by Cytoreductive Nephrectomy in mRCC

February 18th 2020

Ulka Vaishampayan, MD, discusses the considerations when giving patients with metastatic renal cell carcinoma systemic therapy followed by cytoreductive nephrectomy.

Dr. Fakhri on Ongoing Clinical Trials in CLL

February 18th 2020

Bita Fakhri, MD, MPH, assistant professor of medicine in the Division of Hematology/Oncology at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses ongoing clinical trials in chronic lymphocytic leukemia (CLL).

Dr. Lockhart on Dual-Immunotherapy Strategies in CRC

February 18th 2020

A. Craig Lockhart, MD, MHS, professor and associate director for Regional and Strategic Clinical Research Affiliations, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses dual-immunotherapy strategies in colorectal cancer (CRC).

Dr. Chern on Important Germline and Somatic Mutations in Ovarian Cancer

February 18th 2020

Jeannie Chern, MD, a gynecologic oncologist at Moffitt Cancer Center, discusses important germline and somatic mutations to be aware of in ovarian cancer.

Dr. Patel on the Role of Gilteritinib in FLT3+ AML

February 18th 2020

Prapti Patel, MD, discusses the role of gilteritinib in patients with FLT3-mutated acute myeloid leukemia.

Dr. Costello on the Future of Isatuximab in Relapsed/Refractory Multiple Myeloma

February 18th 2020

Caitlin Costello, MD, discusses the future of isatuximab in relapsed/refractory multiple myeloma.

Dr. Ritchie on the Rationale of the AIM Trial in Relapsed/Refractory MCL

February 18th 2020

David Ritchie, MD, PhD, discusses the rationale of the AIM trial in relapsed/refractory mantle cell lymphoma (MCL).

Dr. Antonarakis on Sipuleucel-T Plus Radium-223 in Bone-Metastatic CRPC

February 15th 2020

Emmanuel S. Antonarakis, MBBCh, professor of oncology, Johns Hopkins Medicine, discusses a phase II trial evaluating the combination of sipuleucel-T (Provenge) plus radium-223 dichloride (Xofigo) versus sipuleucel-T alone in patients with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC).

Dr. Choueiri on Phase I/II Data of MK-6482 in Advanced Clear Cell RCC

February 15th 2020

Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, and Jerome and Nancy Kohlberg Chair and professor of medicine, Harvard Medical School, discusses phase I/II results of a trial evaluating the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma.

Dr. Abramson on the TRANSCEND NHL 001 Trial in Large B-Cell Lymphoma

February 15th 2020

Jeremy S. Abramson, MD, discusses the results of the multicenter phase I TRANSCEND NHL 001 study evaluating the safety and efficacy of lisocabtagene maraleucel in relapsed/refractory large B-cell lymphoma.